The Growing Need for Innovative Neuropathy Solutions
Peripheral neuropathy affects approximately 2.4% of the general population, with prevalence increasing to 8% among older adults. As a healthcare provider, you understand the challenges of managing this complex condition—patients cycling through ineffective pharmaceutical treatments, experiencing diminished quality of life, and ultimately losing faith in conventional care approaches. The treatment landscape for peripheral neuropathy has historically been limited to symptom management through medications like gabapentinoids and antidepressants, which often provide incomplete relief and come with significant side effects.
In this environment, forward-thinking practices are differentiating themselves by adopting clinically proven, non-invasive electromedical technologies that address the underlying pathophysiology of neuropathy while delivering measurable patient outcomes. This is where partnering with Neurogenx transforms both patient care and practice performance.
Understanding the Neurogenx Advantage: FDA-Cleared Technology That Delivers Results
What Makes Neurogenx Different?
The Neurogenx NervePro 2.0 represents a paradigm shift in peripheral neuropathy treatment. As an FDA-cleared, patented electromedical device, it stands as the only system of its kind, utilizing high-frequency electronic wave technology (ranging from 60,000Hz to 400Hz) to deliver therapeutic outcomes that transcend traditional TENS units and basic electrotherapy approaches.
Unlike conventional electrical stimulation devices, the Neurogenx NervePro 2.0 generates a sophisticated bio-compatible waveform that mimics the human body's natural action potentials. This unique signal triggers sustained depolarization of cell membranes, opening voltage-dependent gateways that enable:
Enhanced cellular energy influx to restore proper nerve function
Removal of excess fluid, hydrogen ions, and metabolic waste products that contribute to pain and inflammation
Promotion of nerve healing and enhanced blood flow to affected tissues
Restoration of motor and sensory function through targeted nerve stimulation
Clinical Evidence Supporting Neurogenx
The efficacy of Neurogenx treatments is supported by more than 10 years of proven clinical success, with an impressive 87% of patients experiencing resolution or significant reduction of neuropathy symptoms, including:
Chronic pain and burning sensations
Numbness and tingling
Loss of balance and coordination
Sleep disturbances related to neuropathic discomfort
These outcomes have been validated through independent nerve conduction studies, nerve fiber density tests, and balance plate testing—providing objective evidence of neurological improvement rather than subjective symptom relief alone.
The Business Case: Why Partnering with Neurogenx Enhances Practice Performance
Diversification of Revenue Streams
According to the National Institute of Neurological Disorders and Stroke, peripheral neuropathy represents one of the most common neurological problems encountered in clinical practice. By integrating Neurogenx into your service offerings, you tap into a substantial patient population with significant unmet clinical needs.
The treatment protocol—typically consisting of 20-40 minute sessions, 1-2 times per week for 12-16 weeks—creates a predictable, recurring revenue model. With most patients requiring 16-24 total treatments and a commitment to one-year monitoring and maintenance care, practices develop sustained patient relationships that extend well beyond single consultations or prescription renewals.
Competitive Differentiation in a Crowded Market
Research published in the American Family Physician indicates that peripheral neuropathy is idiopathic in 25% to 46% of cases, meaning conventional diagnostic and pharmaceutical approaches often fail to identify treatable causes or provide adequate relief. This creates significant patient frustration and a clinical gap that Neurogenx effectively addresses.
By offering a non-narcotic, non-invasive solution backed by FDA clearance and clinical evidence, your practice positions itself as an innovative leader in neuropathy care. This differentiation is particularly valuable in attracting patients who have exhausted traditional treatment options and are actively seeking alternatives.
Enhanced Patient Satisfaction and Retention
Patient-reported outcomes remain central to evaluating neuropathy treatment success. A systematic literature review on patient-reported outcome measures in chronic neuropathic pain emphasizes the importance of assessing multiple domains beyond pain intensity, including physical functioning, emotional well-being, and global improvement satisfaction.
Neurogenx treatments directly impact these critical outcome domains. Patients frequently report improvement in symptoms within 3-4 visits, creating positive momentum that reinforces treatment adherence. The non-invasive nature of the therapy—no needles, no surgery, no systemic medications—significantly enhances patient acceptance and reduces barriers to treatment initiation.
Moreover, the visible improvements in nerve conduction studies and objective functional assessments provide patients with tangible evidence of therapeutic progress, fostering trust and long-term loyalty to your practice.
Seamless Integration Across Multiple Specialties
One of Neurogenx's most compelling advantages for providers is its versatility across diverse practice settings:
Neurologists can utilize Neurogenx as part of comprehensive diagnostic and therapeutic protocols for patients with confirmed peripheral neuropathy
Primary Care Physicians can offer specialized neuropathy treatment without requiring extensive subspecialty training or referrals
Podiatrists can address diabetic peripheral neuropathy and foot-related neuropathic conditions that significantly impact patient mobility and quality of life
Chiropractors can integrate Neurogenx into musculoskeletal treatment plans for patients experiencing neuropathic pain components
This cross-specialty applicability means practices of virtually any type can successfully implement and benefit from Neurogenx technology.
The Science Behind Superior Outcomes: How Neurogenx Works
Combination Electrochemical Therapy (CET)
The Neurogenx treatment protocol employs Combination Electrochemical Therapy (CET), which can be delivered as either standalone electronic signal therapy or augmented with targeted, low-dose local anesthetics when needed. This integrated approach—sometimes called an Integrated Nerve Block—provides several therapeutic advantages:
Early pain management through selective anesthetic application, improving initial patient comfort and engagement
Increased nerve membrane permeability, allowing the electronic signal to penetrate more effectively
Accelerated therapeutic results through synergistic electrochemical mechanisms
Progressive reduction of anesthetic dependence as nerve function improves, with final treatment phases using electronic signal alone
Evidence-Based Mechanisms of Action
Research from StatPearls on peripheral neuropathy emphasizes that effective neuropathy treatment must address not only pain symptoms but also the underlying pathophysiology of nerve damage and dysfunction. Neurogenx accomplishes this through multiple therapeutic mechanisms:
Cellular Energy Restoration: The bio-compatible waveform generated by the NervePro 2.0 mimics natural nerve action potentials, facilitating sustained membrane depolarization. This allows damaged cells to receive necessary energy inputs for metabolic normalization and healing.
Waste Product Elimination: By maintaining open voltage-gateways, the electronic signal facilitates the removal of accumulated hydrogen ions, inflammatory mediators, and metabolic waste products that perpetuate the pain-inflammation cycle.
Neurovascular Enhancement: The therapy promotes increased local blood circulation, delivering oxygen and nutrients essential for nerve regeneration while removing metabolic byproducts that contribute to ongoing damage.
Nerve Fiber Regeneration: Unlike purely symptomatic treatments, Neurogenx facilitates actual nerve healing, as demonstrated by post-treatment increases in epidermal nerve fiber density documented six months following treatment completion.
Implementing Neurogenx in Your Practice: The Partnership Advantage
Comprehensive Provider Support
When you partner with Neurogenx, you gain access to far more than just FDA-cleared medical equipment. The Neurogenx partnership model includes:
Clinical training and certification ensuring your team can confidently and competently deliver treatments
Practice integration support to seamlessly incorporate Neurogenx into your existing workflows
Marketing and patient education resources to effectively communicate the benefits of this advanced therapy
Ongoing technical and clinical support to optimize outcomes and address any challenges
Benefit coordination assistance to help patients navigate insurance coverage and financing options
Patient Selection and Screening
Neurogenx treatments are appropriate for a wide range of neuropathic conditions resulting from:
Diabetes and metabolic disorders
Chemotherapy-induced peripheral neuropathy (CIPN)
Post-surgical nerve damage
Injury and trauma
Complex Regional Pain Syndrome (CRPS)
Idiopathic peripheral neuropathy
Radiculopathy and nerve compression syndromes
Initial patient consultations and evaluations are typically covered by insurance, allowing providers to thoroughly assess candidacy before committing patients to a full treatment course. This approach ensures appropriate patient selection and sets realistic expectations for therapeutic outcomes.
Treatment Protocols and Patient Monitoring
The standard Neurogenx protocol consists of:
Initial evaluation to confirm neuropathy diagnosis and assess symptom severity
Treatment frequency: 1-2 sessions per week
Treatment duration: Typically 12-16 weeks
Total treatment sessions: Most commonly 16-24 sessions
Session length: 20-40 minutes, often delivered as two consecutive 20-minute sessions at different frequency levels
Throughout the treatment course, providers chart patient-reported outcomes, conduct physical examinations, and utilize objective assessment tools such as:
Balance plate testing to evaluate gait, stance, stability, and proprioception
Nerve conduction studies to document neurophysiological improvements
Epidermal nerve fiber density testing (conducted before treatment and six months post-treatment)
Standardized pain and functional assessment scales
This rigorous monitoring protocol not only optimizes individual patient outcomes but also generates the clinical documentation necessary for insurance reimbursement and outcome-based quality metrics.
Addressing Common Provider Questions
Is Neurogenx Different from TENS Units?
This is perhaps the most common question from providers considering Neurogenx. While both technologies deliver electrical stimulation transcutaneously, the NervePro 2.0 is fundamentally different from consumer-grade TENS units:
Power and frequency range: Neurogenx operates at significantly higher therapeutic frequencies (60,000Hz to 400Hz) compared to typical TENS devices
Waveform characteristics: The bio-compatible waveform mimics nerve action potentials, generating prolonged depolarization rather than simple nerve blockade
FDA clearance: Neurogenx is cleared as a medical device for specific therapeutic indications, not merely symptomatic relief
Clinical outcomes: Neurogenx demonstrates objective improvements in nerve conduction and nerve fiber density, indicating actual nerve healing rather than temporary symptom masking
What About Insurance Coverage and Reimbursement?
Insurance coverage for Neurogenx treatments varies by locale and insurance type. However, the FDA-cleared status of the device and the growing body of clinical evidence supporting its efficacy have facilitated broader coverage in recent years.
Neurogenx provides dedicated benefit coordination support to help practices navigate insurance verification and maximize reimbursement. Initial consultations and evaluations are typically covered by insurance, and many patients find that their treatment courses are partially or substantially covered depending on their specific plans.
For patients with limited insurance coverage, Neurogenx centers can offer co-pay, deductible, and financing options to ensure treatments remain accessible and affordable.
Who Can Administer Neurogenx Treatments?
State regulations govern which licensed healthcare professionals can administer Neurogenx treatments. Generally, the following clinicians are authorized:
Physicians (MD, DO)
Nurse Practitioners
Physician Assistants
Physical Therapists (with appropriate licensure and supervision)
Medical Assistants (under physician supervision, where state law permits)
This flexibility allows practices to efficiently deliver treatments using appropriate clinical staff while maintaining physician oversight of treatment plans and patient monitoring.
The Future of Neuropathy Care: Why Now Is the Time to Partner with Neurogenx
Market Dynamics and Patient Demand
The peripheral neuropathy treatment market is experiencing significant growth driven by:
Aging population demographics: As the National Institute of Neurological Disorders and Stroke notes, neuropathy prevalence increases substantially in older populations
Rising diabetes prevalence: Approximately 50% of adults with diabetes will develop peripheral neuropathy during their lifetime, creating a large and growing patient population
Opioid crisis awareness: Patients and providers alike are increasingly seeking non-narcotic pain management alternatives
Limited pharmaceutical efficacy: Recent systematic reviews of pharmacological treatments for neuropathic pain reveal that even recommended agents like duloxetine provide incomplete relief for many patients
This confluence of factors creates an ideal market environment for innovative, evidence-based technologies like Neurogenx.
Competitive Landscape and Positioning
While several FDA-cleared neuromodulation devices have emerged for neuropathy treatment—including implantable spinal cord stimulators from companies like Abbott and Medtronic, as well as other percutaneous and magnetic stimulation devices—Neurogenx occupies a unique position in the treatment algorithm.
Unlike invasive neurostimulators that require surgical implantation and carry associated risks and costs, Neurogenx provides a conservative, non-invasive first-line approach. This positions it ideally for earlier intervention, potentially preventing the progression of neuropathy to stages requiring more aggressive treatments.
Return on Investment Considerations
For practice administrators and physician owners evaluating capital investments in new technologies, Neurogenx presents compelling financial metrics:
Established reimbursement pathways through existing CPT coding structures
High patient acceptance rates due to non-invasive, painless treatment delivery
Low consumable costs relative to treatment revenue
Recurring revenue model with multi-visit treatment protocols
Minimal space requirements for equipment installation and treatment delivery
Cross-specialty applicability maximizing utilization across patient populations
Moreover, practices report that offering advanced neuropathy treatment enhances their overall reputation in the community, attracting new patients not only for neuropathy care but also for other services. This halo effect amplifies the ROI beyond direct treatment revenues.
Taking the Next Step: Transforming Your Practice with Neurogenx
The treatment of peripheral neuropathy represents one of the most significant unmet needs in contemporary medical practice. Traditional pharmaceutical approaches provide incomplete relief for many patients, leaving both providers and patients frustrated by limited options.
By partnering with Neurogenx, you position your practice at the forefront of evidence-based, innovative neuropathy care. The combination of FDA-cleared technology, proven clinical outcomes, comprehensive provider support, and strong patient satisfaction creates a rare opportunity to simultaneously enhance patient care and practice performance.
Key Takeaways for Providers:
Clinical efficacy: 87% of patients experience significant improvement in neuropathy symptoms, validated by objective neurophysiological testing
Practice differentiation: Offer a unique, non-invasive solution unavailable through traditional pharmaceutical approaches
Revenue enhancement: Multi-visit treatment protocols create recurring revenue and long-term patient relationships
Cross-specialty applicability: Successfully integrate Neurogenx across neurology, primary care, podiatry, and chiropractic practices
Comprehensive support: Benefit from clinical training, marketing resources, and ongoing technical assistance
Patient satisfaction: Deliver measurable outcomes that improve quality of life and functional status
Ready to Elevate Your Practice?
Discover how Neurogenx can transform your approach to peripheral neuropathy treatment and elevate your practice outcomes. Visit neurogenx.com to learn more about the technology, review clinical evidence, read provider testimonials, and explore partnership opportunities.
Your patients deserve more than symptom management—they deserve healing. Neurogenx makes that possible.
References and Additional Resources
National Institute of Neurological Disorders and Stroke. "Peripheral Neuropathy." NINDS. https://www.ninds.nih.gov/health-information/disorders/peripheral-neuropathy
Callaghan BC, Price RS, Feldman EL. "Peripheral Neuropathy: Evaluation and Differential Diagnosis." American Family Physician. 2020;102(12):732-739. https://www.aafp.org/pubs/afp/issues/2020/1215/p732.html
Barrell K, Smith AG. "Peripheral Neuropathy." StatPearls. NCBI Bookshelf. October 2022. https://www.ncbi.nlm.nih.gov/books/NBK542220/
Zhai Y, et al. "Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations." Journal of Pain and Symptom Management. 2019. https://pubmed.ncbi.nlm.nih.gov/30508986/
Kabelitz M, et al. "Patient Reported Outcome Measures in Chronic Neuropathic Pain Clinical Trials – A Systematic Literature Review." The Journal of Pain. 2022. https://www.jpain.org/article/S1526-5900(22)00393-5/fulltext
Abbott. "FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy." January 2023. https://abbott.mediaroom.com/2023-01-26-FDA-Approves-Abbotts-Spinal-Cord-Stimulation-for-People-Living-with-Painful-Diabetic-Peripheral-Neuropathy
Medtronic. "Medtronic announces FDA approval of spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy." January 2022. https://news.medtronic.com/2022-01-24-Medtronic-announces-FDA-approval-of-spinal-cord-stimulation-therapy-for-treating-chronic-pain-resulting-from-diabetic-peripheral-neuropathy
Neurogenx. "Innovative Neuropathy Solutions." https://neurogenx.com
